To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

CD4+CD25+ regulatory T ce… - University of Gothenburg, Sweden Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

CD4+CD25+ regulatory T cells in irritable bowel syndrome patients.

Journal article
Authors Nathalie Holmén
Stefan Isaksson
Magnus Simrén
Henrik Sjövall
Lena Öhman
Published in Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society
Volume 19
Issue 2
Pages 119-25
ISSN 1350-1925
Publication year 2007
Published at Institute of Biomedicine, Department of Microbiology and Immunology
Institute of Medicine, Department of Internal Medicine
Pages 119-25
Language en
Links dx.doi.org/10.1111/j.1365-2982.2006...
Keywords Adult, Antigens, CD4, metabolism, Biological Markers, metabolism, Biopsy, Colitis, immunology, pathology, Colon, immunology, pathology, Female, Flow Cytometry, Forkhead Transcription Factors, genetics, Gene Expression, immunology, Humans, Interleukin-2 Receptor alpha Subunit, metabolism, Intestinal Mucosa, immunology, pathology, Irritable Bowel Syndrome, immunology, pathology, Male, Middle Aged, RNA, Messenger, metabolism, T-Lymphocytes, Regulatory, immunology, metabolism
Subject categories Gastroenterology and Hepatology

Abstract

The aetiology of the irritable bowel syndrome (IBS) is incompletely understood. A low-grade colonic inflammation is frequently seen, but it is unclear to what extent this phenomenon contributes to the pathophysiology of IBS. CD4(+)CD25(+) regulatory T cells (Treg) are implicated to play an important role in suppressing intestinal inflammation. We, therefore, examined whether the intestinal inflammatory process in IBS patients is the result of an altered function and/or frequency of CD25(+) Treg cells. Patients with IBS (n = 34), fulfilling the Rome II criteria, were compared with controls (n = 26). The suppressive activity of blood CD25(+) Treg cells was determined and the frequency of colonic and blood CD25(+) Treg cells was analysed by flow cytometry. The expression of the Treg marker, FOXP3 mRNA, in colonic biopsies was determined by reverse transcription-polymerase chain reaction. Blood CD25(+) Treg cells from IBS patients suppressed the proliferation of blood CD4(+)CD25(low/-) T cells. Similar frequencies of CD25(+) Treg cells were recorded in mucosa and blood of IBS patients and controls. FOXP3 mRNA was equally expressed in the colonic mucosa of patients with IBS and controls. In conclusion, the low-grade intestinal inflammation recorded in patients with IBS is not associated with an altered function or frequency of CD25(+) Treg cells.

Page Manager: Webmaster|Last update: 9/11/2012
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?